PMAT variant rs3889348 is associated with metformin-induced gastrointestinal among Chinese Type 2 diabetes patients

Pharmacogenomics. 2023 Jul;24(10):551-560. doi: 10.2217/pgs-2023-0078. Epub 2023 Jul 17.

Abstract

Aim: This study examined intronic gene variants for their association with metformin intolerance in a Chinese population, focusing on the plasma monoamine transporter (PMAT) cis-protein expression quantitative trait loci (cis-eQTL) variant rs3889348. Methods: We recruited Type 2 diabetes patients from two hospitals and identified 111 metformin-intolerant patients using a questionnaire, and selected 206 metformin-tolerant patients from 2180 Type 2 diabetes mellitus patients. Genetic testing revealed an association between adverse gastrointestinal (GI) effects and SLC22A1 and PMAT. Results: The single-nucleotide polymorphism rs3889348 is associated with metformin-induced adverse GI effects. Each additional copy of the G allele increases the score by 5.23 (95% CI: 1.82-8.64; p = 0.003). Patients taking more transporter inhibitors were more likely to respond to metformin-induced GI intolerance (p = 0.042). Conclusion: PMAT cis-eQTL rs3889348 was significantly associated with metformin-induced adverse GI effects.

Keywords: PMAT; Type 2 diabetes; gastrointestinal; metformin; rs3889348.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetes Mellitus, Type 2* / genetics
  • East Asian People / genetics
  • Gastrointestinal Diseases / chemically induced
  • Gastrointestinal Diseases / genetics
  • Humans
  • Hypoglycemic Agents* / adverse effects
  • Metformin* / adverse effects
  • Polymorphism, Single Nucleotide / genetics

Substances

  • Hypoglycemic Agents
  • Metformin
  • SLC29A4 protein, human